FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983199811> ?p ?o ?g. }

• W2983199811 endingPage "4108" @default.
• W2983199811 startingPage "4108" @default.
• W2983199811 abstract "Introduction: Implementation of cellular therapy has transformed the treatment paradigm for diffuse large B-cell lymphoma with sustained responses observed in JULIET and ZUMA-1. Bridging therapies were permitted on the JULIET trial but were excluded on ZUMA-1 (Schuster, NEJM, 2019; Locke, Lancet, 2018). CAR T-cell therapy (CAR-T) is indicated after 2 lines of therapy; however, in the standard of care setting (SOC), the choice and timing of prior salvage therapies can vary widely. We sought to characterize common therapies received immediately prior to CAR-T administration at our institution. Patients and Methods: We conducted a retrospective study of all adult patients who had a successful product manufactured for commercial CAR-T with tisagenlecleucel (tisa-cel) or axicabtagene ciloleucel (axi-cel) therapy at the University of Pennsylvania between 10/2017 and 7/2019. Demographics, therapy prior to CAR-T including bridging therapies, and status of disease by physician report in a binary assessment of progression prior to CAR-T were collected. Bridging therapy was defined as therapy given after T-cell apheresis but prior to CAR-T infusion, not including lymphodepleting chemotherapy (LD). Therapies were combined into groups for analysis: small molecule targeted agents +/-radiation, immunotherapy+/-radiation, chemoimmunotherapy +/-radiation, and radiation alone. Results: We identified 64 patients with non-Hodgkin lymphoma for this analysis. Prior to eligibility evaluation for CAR-T, all patients received at least 2 lines of prior therapy; with 25% receiving prior autologous stem cell transplant and one patient receiving prior allogeneic stem cell transplant. Eleven patients (17%) received prior bendamustine and/or purine analogue therapy. At the time of leukapheresis, median ECOG performance status was 1 (Range 0-3). Of the 64 patients, 49 patients (77%) proceeded to cellular therapy, 9 patients (14%) died prior to CAR-T infusion and 6 patients (9%) are awaiting infusion and were not included in the analysis of bridging therapy. The median time from the last therapy prior to CAR-T infusion, including bridging therapy, was 28 days (range 0-406 days). Of those who received CAR-T, 39% received axi-cel and 61% received tisa-cel. At the time of data cutoff, 22 of 49 patients had progressive disease post CAR-T infusion. Of these patients, 10 patients (45%) entered CAR-T with progressive disease and 4 patients (18%) had stable disease. In patients not having progression post CAR-T therapy (27 of 49 patients), 4 patients (15%) had PD entering LD and CAR-T infusion. Of the patients who successfully received CAR-T, 34 of 49 pts required bridging therapy (69%). Bridging therapy was initiated by the treating physician for reducing tumor burden or palliation of lymphoma symptoms while awaiting CAR-T infusion. Therapies most commonly received were combination chemoimmunotherapy (21%), obinutuzumab (15%), radiation (15%), ibrutinib (15%), systemic therapy + radiation therapy (12), lenalidomide (6%), cyclophosphamide (3%), and rituximab/lenalidomide (3%). For patients receiving targeted agents, one of 8 patients (13%) had progressive disease (PD) at the time of CAR-T infusion. Two of 9 patients (22%) receiving immunotherapy had PD at the time of CAR-T infusion. In the chemoimmunotherapy group, 3 of 12 patients (25%) had PD at the time of CAR-T infusion. Five patients received only radiation as bridging and 1 had PD at time of CAR-T infusion. Conclusion: Our single-institution experience with CAR-T noted that most patients required bridging therapy prior to CAR-T infusion but no single bridging therapy was identified as preferable. Rapid disease progression through bridging entering into CAR-T therapy may predict for a lack of response. Further analysis is ongoing for other factors. Of note, systemic therapy was tailored to patients by treating physician with a trend toward more targeted therapy, with radiation providing site specific disease control. Further study is warranted to determine optimal bridging as well as the utility of response assessment immediately prior to the time of T-cell reinfusion. Disclosures Dwivedy Nasta: Merck: Consultancy, Other: data safety monitorin; Roche: Research Funding; Rafael: Research Funding; Millenium/takeda: Research Funding; Debiopharm: Research Funding; Aileron: Research Funding; ATARA: Research Funding; Pharmacyclics: Research Funding; Celgene: Honoraria; 47 (Forty Seven): Research Funding. Hughes:Genzyme: Membership on an entity's Board of Directors or advisory committees; Acerta Pharna/HOPA: Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees. Landsburg:Seattle Genetics: Speakers Bureau; Seattle Genetics: Speakers Bureau; Takeda: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Curis, INC: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Curis, INC: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Research Funding; Triphase: Research Funding; Triphase: Research Funding. Chong:Novartis: Consultancy; Merck: Research Funding; Tessa: Consultancy. Barta:Celgene: Research Funding; Bayer: Consultancy, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees; Merck: Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees; Celgene: Research Funding; Mundipharma: Honoraria; Seattle Genetics: Honoraria, Research Funding; Takeda: Research Funding; Mundipharma: Honoraria. Frey:Novartis: Research Funding. Gerson:Abbvie: Consultancy; Seattle Genetics: Consultancy; Pharmacyclics: Consultancy. Porter:Immunovative: Membership on an entity's Board of Directors or advisory committees; Glenmark Pharm: Membership on an entity's Board of Directors or advisory committees; Kite: Membership on an entity's Board of Directors or advisory committees; Wiley and Sons: Honoraria; Genentech: Employment; American Board of Internal Medicine: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; Incyte: Membership on an entity's Board of Directors or advisory committees. Ruella:AbClon: Membership on an entity's Board of Directors or advisory committees; Nanostring: Consultancy, Speakers Bureau; Novartis: Patents & Royalties: CART for cancer. Svoboda:AstraZeneca: Consultancy; Celgene: Research Funding; Incyte: Research Funding; Pharmacyclics: Consultancy, Research Funding; Kyowa: Consultancy; Merck: Research Funding; BMS: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding. Schuster:Novartis: Other: a patent (with royalties paid to Novartis) on combination therapies of CAR and PD-1 inhibitors.; Nordic Nanovector, Pfizer, AstraZeneca, Loxo Oncology, Acerta, and Celgene: Honoraria; Novartis, Celgene, Genentech, Merck, Pharmacyclics, Acerta, and Gilead: Other: Grants, Research Funding; Novartis, Nordic Nanovector, and Pfizer: Membership on an entity's Board of Directors or advisory committees." @default.
• W2983199811 created "2019-11-22" @default.
• W2983199811 creator A5005058090 @default.
• W2983199811 creator A5015896987 @default.
• W2983199811 creator A5019666650 @default.
• W2983199811 creator A5034653699 @default.
• W2983199811 creator A5039776999 @default.
• W2983199811 creator A5042844727 @default.
• W2983199811 creator A5047973111 @default.
• W2983199811 creator A5070683930 @default.
• W2983199811 creator A5075190622 @default.
• W2983199811 creator A5080050959 @default.
• W2983199811 creator A5080630441 @default.
• W2983199811 creator A5088286702 @default.
• W2983199811 creator A5088355904 @default.
• W2983199811 creator A5089409657 @default.
• W2983199811 creator A5090230371 @default.
• W2983199811 date "2019-11-13" @default.
• W2983199811 modified "2023-09-30" @default.
• W2983199811 title "A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy" @default.
• W2983199811 doi "https://doi.org/10.1182/blood-2019-131399" @default.
• W2983199811 hasPublicationYear "2019" @default.
• W2983199811 type Work @default.
• W2983199811 sameAs 2983199811 @default.
• W2983199811 citedByCount "13" @default.
• W2983199811 countsByYear W29831998112020 @default.
• W2983199811 countsByYear W29831998112021 @default.
• W2983199811 countsByYear W29831998112022 @default.
• W2983199811 countsByYear W29831998112023 @default.
• W2983199811 crossrefType "journal-article" @default.
• W2983199811 hasAuthorship W2983199811A5005058090 @default.
• W2983199811 hasAuthorship W2983199811A5015896987 @default.
• W2983199811 hasAuthorship W2983199811A5019666650 @default.
• W2983199811 hasAuthorship W2983199811A5034653699 @default.
• W2983199811 hasAuthorship W2983199811A5039776999 @default.
• W2983199811 hasAuthorship W2983199811A5042844727 @default.
• W2983199811 hasAuthorship W2983199811A5047973111 @default.
• W2983199811 hasAuthorship W2983199811A5070683930 @default.
• W2983199811 hasAuthorship W2983199811A5075190622 @default.
• W2983199811 hasAuthorship W2983199811A5080050959 @default.
• W2983199811 hasAuthorship W2983199811A5080630441 @default.
• W2983199811 hasAuthorship W2983199811A5088286702 @default.
• W2983199811 hasAuthorship W2983199811A5088355904 @default.
• W2983199811 hasAuthorship W2983199811A5089409657 @default.
• W2983199811 hasAuthorship W2983199811A5090230371 @default.
• W2983199811 hasBestOaLocation W29831998111 @default.
• W2983199811 hasConcept C10882517 @default.
• W2983199811 hasConcept C121608353 @default.
• W2983199811 hasConcept C126322002 @default.
• W2983199811 hasConcept C141071460 @default.
• W2983199811 hasConcept C143998085 @default.
• W2983199811 hasConcept C2776694085 @default.
• W2983199811 hasConcept C2777701055 @default.
• W2983199811 hasConcept C2779338263 @default.
• W2983199811 hasConcept C2780653079 @default.
• W2983199811 hasConcept C2780775027 @default.
• W2983199811 hasConcept C2780790343 @default.
• W2983199811 hasConcept C28328180 @default.
• W2983199811 hasConcept C2911194787 @default.
• W2983199811 hasConcept C3875195 @default.
• W2983199811 hasConcept C509974204 @default.
• W2983199811 hasConcept C54355233 @default.
• W2983199811 hasConcept C71924100 @default.
• W2983199811 hasConcept C86803240 @default.
• W2983199811 hasConceptScore W2983199811C10882517 @default.
• W2983199811 hasConceptScore W2983199811C121608353 @default.
• W2983199811 hasConceptScore W2983199811C126322002 @default.
• W2983199811 hasConceptScore W2983199811C141071460 @default.
• W2983199811 hasConceptScore W2983199811C143998085 @default.
• W2983199811 hasConceptScore W2983199811C2776694085 @default.
• W2983199811 hasConceptScore W2983199811C2777701055 @default.
• W2983199811 hasConceptScore W2983199811C2779338263 @default.
• W2983199811 hasConceptScore W2983199811C2780653079 @default.
• W2983199811 hasConceptScore W2983199811C2780775027 @default.
• W2983199811 hasConceptScore W2983199811C2780790343 @default.
• W2983199811 hasConceptScore W2983199811C28328180 @default.
• W2983199811 hasConceptScore W2983199811C2911194787 @default.
• W2983199811 hasConceptScore W2983199811C3875195 @default.
• W2983199811 hasConceptScore W2983199811C509974204 @default.
• W2983199811 hasConceptScore W2983199811C54355233 @default.
• W2983199811 hasConceptScore W2983199811C71924100 @default.
• W2983199811 hasConceptScore W2983199811C86803240 @default.
• W2983199811 hasIssue "Supplement_1" @default.
• W2983199811 hasLocation W29831998111 @default.
• W2983199811 hasOpenAccess W2983199811 @default.
• W2983199811 hasPrimaryLocation W29831998111 @default.
• W2983199811 hasRelatedWork W2921642542 @default.
• W2983199811 hasRelatedWork W2922707684 @default.
• W2983199811 hasRelatedWork W2953936851 @default.
• W2983199811 hasRelatedWork W2972945473 @default.
• W2983199811 hasRelatedWork W3194437930 @default.
• W2983199811 hasRelatedWork W3195202932 @default.
• W2983199811 hasRelatedWork W3215426138 @default.
• W2983199811 hasRelatedWork W4296628476 @default.
• W2983199811 hasRelatedWork W4318448118 @default.
• W2983199811 hasRelatedWork W4381331157 @default.
• W2983199811 hasVolume "134" @default.
• W2983199811 isParatext "false" @default.

• next